300 related articles for article (PubMed ID: 24694588)
21. Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats.
Mahfoz AM; El-Latif HA; Ahmed LA; Hassanein NM; Shoka AA
Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1315-1324. PubMed ID: 27612855
[TBL] [Abstract][Full Text] [Related]
22. Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats.
Matavelli LC; Siragy HM
J Cardiovasc Pharmacol; 2013 Jan; 61(1):17-22. PubMed ID: 23011470
[TBL] [Abstract][Full Text] [Related]
23. Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice.
Hashimoto A; Takeda Y; Karashima S; Kometani M; Aono D; Demura M; Higashitani T; Konishi S; Yoneda T; Takeda Y
Hypertens Res; 2020 Oct; 43(10):1099-1104. PubMed ID: 32398797
[TBL] [Abstract][Full Text] [Related]
24. Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart.
Campbell DJ; Zhang Y; Kelly DJ; Gilbert RE; McCarthy DJ; Shi W; Smyth GK
Clin Exp Pharmacol Physiol; 2011 Sep; 38(9):623-31. PubMed ID: 21736602
[TBL] [Abstract][Full Text] [Related]
25. Renoprotective effects of direct renin inhibition in glomerulonephritis.
Miyata K; Satou R; Inui D; Katsurada A; Seth D; Davis A; Urushihara M; Kobori H; Mitchell KD; Navar LG
Am J Med Sci; 2014 Oct; 348(4):306-14. PubMed ID: 24165783
[TBL] [Abstract][Full Text] [Related]
26. Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Ferrario CM
Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):15-29. PubMed ID: 22222314
[TBL] [Abstract][Full Text] [Related]
27. Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats.
Rakusan D; Kujal P; Kramer HJ; Husková Z; Vanourková Z; Vernerová Z; Mrázová I; Thumová M; Cervenka L; Vanecková I
Am J Physiol Renal Physiol; 2010 Oct; 299(4):F758-66. PubMed ID: 20668096
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
29. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
30. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice.
Ichihara A; Suzuki F; Nakagawa T; Kaneshiro Y; Takemitsu T; Sakoda M; Nabi AH; Nishiyama A; Sugaya T; Hayashi M; Inagami T
J Am Soc Nephrol; 2006 Jul; 17(7):1950-61. PubMed ID: 16738017
[TBL] [Abstract][Full Text] [Related]
31. Potential benefits of aliskiren beyond blood pressure reduction.
Weintraub HS; Tran H; Schwartzbard A
Cardiol Rev; 2011; 19(2):90-4. PubMed ID: 21285669
[TBL] [Abstract][Full Text] [Related]
32. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells.
Batenburg WW; de Bruin RJ; van Gool JM; Müller DN; Bader M; Nguyen G; Danser AH
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1151-7. PubMed ID: 18388329
[TBL] [Abstract][Full Text] [Related]
33. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats.
Pilz B; Shagdarsuren E; Wellner M; Fiebeler A; Dechend R; Gratze P; Meiners S; Feldman DL; Webb RL; Garrelds IM; Jan Danser AH; Luft FC; Müller DN
Hypertension; 2005 Sep; 46(3):569-76. PubMed ID: 16103264
[TBL] [Abstract][Full Text] [Related]
34. Renin-angiotensin system blockade alone or combined with ET
Sedláková L; Čertíková Chábová V; Doleželová Š; Škaroupková P; Kopkan L; Husková Z; Červenková L; Kikerlová S; Vaněčková I; Sadowski J; Kompanowska-Jezierska E; Kujal P; Kramer HJ; Červenka L
Clin Exp Hypertens; 2017; 39(2):183-195. PubMed ID: 28287881
[TBL] [Abstract][Full Text] [Related]
35. Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?
Hollenberg NK; Fisher ND; Nussberger J; Moukarbel GV; Barkoudah E; Danser AH
J Hypertens; 2011 Dec; 29(12):2454-61. PubMed ID: 22002336
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of fluorescence energy transfer system for imaging the renoprotective effects of aliskiren in diabetic mice.
Kidokoro K; Satoh M; Itano S; Kuwabara A; Sasaki T; Kashihara N
J Renin Angiotensin Aldosterone Syst; 2016; 17(2):1470320315625704. PubMed ID: 27216079
[TBL] [Abstract][Full Text] [Related]
37. The Effect of Combined Treatment with the (Pro)Renin Receptor Blocker HRP and Quinapril in Type 1 Diabetic Rats.
Kökény G; Fang L; Révész C; Mózes MM; Vörös P; Szénási G; Rosivall L
Kidney Blood Press Res; 2017; 42(1):109-122. PubMed ID: 28359068
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
39. Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.
Varagic J; Ahmad S; VonCannon JL; Moniwa N; Brosnihan KB; Wysocki J; Batlle D; Ferrario CM
Am J Hypertens; 2013 May; 26(5):583-90. PubMed ID: 23459599
[TBL] [Abstract][Full Text] [Related]
40. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
Sepehrdad R; Frishman WH; Stier CT; Sica DA
Cardiol Rev; 2007; 15(5):242-56. PubMed ID: 17700383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
